Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Joe...appreciate your efforts to keep the board informed. Some very interesting posts. Thanks!
From US News yesterday: "How Many People Have Long COVID? The Statistics Are ‘Pretty Scary’ "
https://www.usnews.com/news/health-news/articles/2022-07-08/how-many-people-have-long-covid-the-statistics-are-pretty-scary
Just got my 4FOR4 order of Tollovid. Noticed that this is a new batch with an expiration of 12/23.
Thought this CDC report out today was interesting...especially the following:
"Known multilayered prevention measures, including nonpharmaceutical interventions, up-to-date COVID-19 vaccination, and therapeutics, can prevent hospitalization and subsequent severe COVID-19 outcomes among immunocompromised persons."
https://www.cdc.gov/mmwr/volumes/71/wr/mm7127a3.htm?s_cid=mm7127a3_w
Thanks for the threads.
Don't know if you've noticed the recent Tollovid Points program. With the 4FOR4 buy I picked up another 2000 points. Each 500 points equals $5.
Just took advantage of the 4FOR4 offer on mytollovid.com. Saved $198.
For what it's worth...Todos sent out e-mails advertising a Fourth of July sale for Tollovid. They are advertising 4 bottles of Tollovid for $400 with a discount code of 4FOR4. At the bottom of the ad is a link to Buy Now...which I tried. Evidently the discount code won't work until the actual 4th.
Ominous change in Covid cases...and the situation is probably more dire since many people are testing at home and not reporting the results.
https://charts.medriva.com/us
"Bad news for Paxlovid? Coronavirus can find multiple ways to evade COVID-19 drug
Lab studies identify resistance mutations in SARS-CoV-2’s protease, and some circulating variants have them"
https://www.science.org/content/article/bad-news-paxlovid-coronavirus-can-find-multiple-ways-evade-covid-19-drug
Key comments from today's announcement:
“We believe the correlative biomarker data, in addition to the positive clinical results previously reported in hospitalized patients primarily from the Delta variant wave, should elevate Tollovir’s profile in the eyes of regulators,” Commissiong said. “After review with our regulatory attorneys, we believe that if additional data from our planned open label extension of the study (N up to 46, all to receive Tollovir) are consistent with the data from the blinded, placebo-controlled trial segment (N = 20 in Part 2), we will apply for an Emergency Use Authorization in the United States and Europe,” he added.
Todos Medical plans open label extension of Phase 2 trial of Tollovir in hospitalized Covid patients after encouraging biomarker data
https://www.proactiveinvestors.com/companies/news/986339/todos-medical-plans-open-label-extension-of-phase-2-trial-of-tollovir-in-hospitalized-covid-patients-after-encouraging-biomarker-data-986339.html?viewSource=TwitterUS
Todos Medical Announces Positive Biomarker Data from Phase 2 Trial of Tollovir in Hospitalized COVID-19 Patients
https://investor.todosmedical.com/news-events/press-releases/detail/205/todos-medical-announces-positive-biomarker-data-from-phase
Good point!
New development from Twitter:
#todosmedical’s
@G_Commish
will be presenting at #PMWC22 in Silicon Valley on June 30. Don’t miss his session “Developing New Antiviral Compounds Discovered by Quantum Mechanism-Based Drug Design” to learn about Tollovir, a #novel #therapeutic candidate for #Covid. See you there!
https://twitter.com/todosmedical/status/1541854561459216387/photo/1
Got confirmation yesterday that the trial for Case No.: 5:20-00425 EJD USA v Mark Schena starts 7/26/2022 at 9:00 AM.
I'm unsure. The prosecuting attorney told me Aug 8. I'll try to get clarification.
Mike
The case you referenced is discussed here:
https://casetext.com/case/us-v-schena-1
It appears to be the same.
Proactive Article:
Todos Medical retains Moneta Advisory Partners for planned listing and crowdfunding
https://www.proactiveinvestors.com/companies/news/985456/todos-medical-retains-moneta-advisory-partners-for-planned-listing-and-crowdfunding-985456.html
Thanks for the Twitter feeds...some very interesting banter and information.
Salient quotes from today's PR:
“Recent case studies reporting that the Company’s dietary supplement product Tollovid was able to help those users deal with many of their Long COVID-related symptoms really brought to light the tremendous first mover advantage 3CL Pharma has in this quickly emerging Long COVID healthcare market,” said Jon Najarian, Managing Partner at Moneta. “I’ve been following the Tollovid story for some time. I myself used the Tollovid Max version of the product for a week during the early winter period and I believe it made a big difference for me. With the emergence of Long COVID as a potentially enormous public healthcare problem negatively impacting individual freedom, worker productivity and driving huge numbers of people towards disability, now is the time for action.”
“The Moneta team is very well positioned to help Todos get to the next level,” said Gerald Commissiong, President & CEO at Todos Medical. “We intend to work very closely with them in the months ahead as we move towards a national exchange listing for Todos and a crowdfunding for 3CL Pharma that already has over 8,000 customers who have purchased Tollovid with generally very favorable results.”
The use of Moneta Advisory Partners as Strategic Advisors could/should be the catalyst that Todos needs to advance.
Todos Medical Retains Moneta Advisory Partners as Strategic Advisors for National Exchange Listing and 3CL Pharma Spinoff
https://investor.todosmedical.com/news-events/press-releases/detail/203/todos-medical-retains-moneta-advisory-partners-as-strategic
The entire podcast is very informative and Gerald does a great job responding to the questions presented. Having said this, if you don't have time for the whole podcast and are primarily interested in hearing from Dr. Arad you can find her discussion starting at the 44 minute mark.
Apple Podcast: Episode 38: Gerald Commissiong and Dr Dorit Arad - Tollovid
Living with long covid.
https://podcasts.apple.com/gb/podcast/tlc-sessions-living-with-long-covid/id1574768076?i=1000567258594
JFB, thanks for the Twitter posts. Data from the LC study should be out soon and could generate new interest in Todos.
New Zero Hedge article on recent development regarding Paxlovid and comments on Ivermectin and Tollovid.
https://www.zerohedge.com/news/2022-06-17/miracle-pill-paxlovid-benched-peoples-antivirals-ivermectin-tollovid-sub
Thanks for all the Twitter posts...very interesting.
I think that some of your concerns are being addressed by the new Tolovid survey which asks the following: "Have you benefited from Tollovid's Immune Support?" I completed my survey this morning and received 20% off my new order for Tollovid.
Very interesting development; thanks for posting. Looks like Tollovid could become the preferred Covid solution for the "standard-risk" population.
Thanks for providing your take on the articles. There is so much to learn about this insidious beast.
Thanks. There have been many very positive Press Releases for Todos, especially during the past year. In my opinion the stock would have significantly increased in value had it not been for the continual dilution. I still think the company has great potential.
Sadly, for many months there has been a fairly strong correlation between "good news" and price declines in the stock. The Achilles heel for Todos, as with Amarantus, has always been the toxic debt that the firms incurred. Until Todos can get a handle on its finances, the stock will languish. If we were to see numerous SEC Form 4's being filed indicating that Todos executives were purchasing shares of the company, or if Todos were to buy back shares, then we would see more real interest in the company.
Two current NY Times articles regarding Covid:
https://www.nytimes.com/2022/06/13/opinion/covid-immunity.html
https://www.nytimes.com/2022/06/12/health/ivermectin-covid-recovery-time.html
This seems to be a pretty significant development and potentially lucrative product for a large market. They have started production of the new UTI PCR Panel and are preparing to launch it commercially, but I don't see any mention of approvals from regulatory authorities.
Case No. CR20-70721-MAG United States of America V Mark Schena goes to trial August 9, 2022.
Thanks to you and misiu for this information. I don't recall seeing much emphasis regarding holding off on exercise for such an extended period of time after having Covid.